Coronary artery disease
Conditions
Interventions
The first group will receive a 600mg loading dose of clopidogrel directly
before start of PCI (in-laboratory group), while the second group will receive
clopidogrel 75mg once daily 3 days before dia
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Adult men and women aged at least 18 years - Scheduled for diagnostic CAG due to suspected obstructive coronary artery disease
Exclusion criteria
Exclusion criteria: - Inability to give informed consent (e.g., language barrier) - Presence of contra-indications for the use of clopidogrel - Patients using clopidogrel for other reasons than the scheduled diagnostic CAG - Patients using P2Y12 inhibitors other than clopidogrel - Patients using VKA - Patients using DOAC/NOAC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in occurrence of the composite endpoint 'Net Adverse Clinical Events' (NACE; all-cause death, myocardial infarction, definite/probable stent thrombosis, stroke and BARC type 2, -3 or -5 bleeding) assessed at 30 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the difference in : - Bleeding Academic Research Consortium (BARC) -2, -3 and -5 bleeding in-hospital and at 30 days - The composite endpoint 'Patient Oriented Clinical Events' (POCE; all-cause death, stroke, myocardial infarction, repeat revascularization) in-hospital and at 30 days - Individual endpoints of the composite endpoints POCE / NACE in-hospital and at 30 days | — |
Countries
Netherlands
Outcome results
None listed